Pasithea Therapeutics Corp.
Clinical trials sponsored by Pasithea Therapeutics Corp., explained in plain language.
-
New pill hopes to shrink painful NF1 tumors without surgery
Disease control Recruiting nowThis early-stage study tests a daily pill called PAS-004 in adults with neurofibromatosis type 1 (NF1) who have at least one symptomatic, inoperable nerve tumor (plexiform neurofibroma). The main goals are to find safe doses and understand side effects. The study has two parts: P…
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New cancer pill enters first human safety trial
Disease control Recruiting nowThis is the first study in people testing an experimental pill called PAS-004 for advanced solid tumors that have specific genetic mutations (RAS, NF1, or RAF) or have stopped responding to standard treatments. The main goals are to find a safe dose, understand the side effects, …
Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC